Shyamala Navada, MD of @MountSinaiNYC discusses the phase II study of oral rigosertib combined with azacitidine as first line therapy in patients with HR-MDS.
Phase II Study of Oral Rigosertib #ASH19 @MountSinaiNYC
Shyamala Navada, MD of @MountSinaiNYC discusses the phase II study of oral rigosertib combined with azacitidine as first line therapy in patients with HR-MDS.